Organigram Q3 Sales Grow to $3.7 Million | CashCropToday
0 Shares 527 Views

Organigram Q3 Sales Grow to $3.7 Million

July 31, 2018
527 Views

Organigram Holdings Inc. (TSX VENTURE: OGI) (OTCQB: OGRMF), a medical cannabis cultivation and distribution company out of New Brunswick, Canada has announced its Q3 sales for 2018. Within the three month period the company was able to produce $3.7 million dollars in sales. This total surpasses what Organigram was capable of selling in the entire fiscal year of 2017.

Organigram has made a number of strategic moves during this period. In May, Organigram received its “License for Controlled Drugs and Substances” from Health Canada and its “Permit to Export Cannabis” license. This lead to the company’s first international export of medicinal cannabis to Australia in July.

Within the third quarter the company recorded the sale of 303,428 grams of dried cannabis flower, 768,400 milliliters of cannabis oil, and had accomplished rising its registered medical patient list to a company best of 15,316.

Organigram’s assets at the end of Q3 is as follows:

  • $156 million in cash and short-term investments (up from $34 million at the August 31, 2017 year-end);
  • $26.9 million in combined biological assets and inventories (up from $5.4 million at year-end);
  • $83 million in property, plant and equipment (up from $45 million at year-end);
  • $9 million in current liabilities (up from $6 million at year-end);
  • $98 million in long-term debt and convertible debentures (up from $3 million at year-end)

You may be interested

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon
Market Watch
269 views
Market Watch
269 views

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon

Editor - November 27, 2018

Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition
Global
192 views
Global
192 views

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition

Editor - November 26, 2018

Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials
Manufacturing
189 views
Manufacturing
189 views

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials

Editor - November 26, 2018

GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…

Leave a Comment

Your email address will not be published.

Most from this category

%d bloggers like this: